Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Authors: Yi‐Long Wu, Ying Cheng, Jianying Zhou, Shun Lü, Yiping Zhang, Jun Zhao, Dong‐Wan Kim, Ross A. Soo, Sang‐We Kim, Hongming Pan, Yuh‐Min Chen, Chih‐Feng Chian, Xiaoqing Liu, Daniel S.W. Tan, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, Keunchil Park, James Chih‐Hsin Yang, Yi‐Long Wu, Xiaoqing Liu, Zhe Liu, Shun Lu, Xi Chen, Hongming Pan, Mengzhao Wang, YU Shi-ying, Helong Zhang, Yiping Zhang, Jian Fang, Wei Li, Jianying Zhou, Jun Zhao, Ying Cheng, Chih-Hsin Yang, Gee‐Chen Chang, Yuh‐Min Chen, Te‐Chun Hsia, Chih‐Feng Chian, Cheng-Ta Yang, Chin‐Chou Wang, Sang‐We Kim, Keunchil Park, Dong‐Wan Kim, Byoung Chul Cho, Ki Hyeong Lee, Young‐Chul Kim, Ho Jung An, In Sook Woo, Y. Choi, Sang Won Shin, Jong Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Ross A. Soo, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles, Martín Emilio Lázaro Quintela, Enriqueta Felip Font, Anne‐Marie C. Dingemans, Lynne A. Bui - The Lancet 2020 cited by 258